Blog -Detail
Maersk führt speziellen Reefer-Rail-Service für Pharma-Kühlkettenexporte ein
Maersk Launches Dedicated Reefer Rail Service for India’s Pharma Cold Chain
Was ist passiert
Maersk has launched its first dedicated weekly reefer rail service connecting Hyderabad’s pharmaceutical manufacturing cluster with Nhava Sheva Port near Mumbai. The service was developed in partnership with Container Corporation of India and is designed for pharmaceutical exporters that require reliable temperature-controlled logistics.
The new corridor gives pharma exporters a scheduled cold-chain rail option between one of India’s major pharmaceutical production hubs and a key export gateway. Maersk says the service is intended to provide predictable logistics while reducing greenhouse gas emissions compared with road transport.
Wie es funktioniert
The Hyderabad–Nhava Sheva corridor operates as an end-to-end cold chain service. Under a single-window model, Maersk manages inland rail, Seefracht, and shipment visibility across the journey. The service runs on a fixed weekly schedule using 40-foot refrigerated containers.
Each shipment includes pre-trip inspection compliance and selected reefer containers aligned with pharmaceutical quality requirements. Maersk says several leading pharmaceutical manufacturers are already using the service, with more customers in the onboarding pipeline.
The company also states that the service can reduce carbon dioxide emissions by up to 3,000 tonnes annually compared with road transport, making it both a cold chain reliability project and a lower-emission logistics solution.
Warum ist es wichtig
Pharmaceutical exports depend on temperature integrity, Dokumentation, and route predictability. Road transport can face congestion, Routenvariabilität, and higher emissions, while dedicated reefer rail can offer a more controlled and scheduled alternative for long inland movements.
Hyderabad is a major pharmaceutical manufacturing hub, so connecting it directly with Nhava Sheva through a dedicated reefer rail service can reduce logistics uncertainty for exporters. This is especially relevant for medicines, Biologika, and other temperature-sensitive healthcare products moving into global markets.
B2B-Auswirkungen
For pharmaceutical exporters, the new service may improve planning reliability, temperature-control confidence, and export lane consistency. A scheduled rail model can help companies align production, Dokumentation, port handover, and ocean freight with fewer inland logistics variables.
Für Kühlkettenverpackungen und Lieferantenüberwachung, the service may increase demand for qualified packaging, Temperaturlogger, reefer container validation, shipment visibility tools, and lane risk assessment. Rail-based pharma cold chain still requires strong packaging and data support to maintain product quality from factory to destination.
For B2B logistics buyers, the key takeaway is that pharma cold chain is becoming more multimodal. Schiene, Kühlcontainer, shipment visibility, and ocean freight are being combined into integrated export solutions rather than handled as separate logistics steps.
